Stay updated on Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial
Sign up to get notified when there's something new on the Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial page.

Latest updates to the Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedFooter revision label updated from v3.4.1 to v3.4.2; no impact on study content or page usability.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision metadata was updated: Revision: v3.4.1 was added and Revision: v3.4.0 was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedGlossary toggle is now shown on the page. Minor textual updates include capitalization changes for 'Last Update Submitted' and 'No FEAR Act data', and a new revision label v3.4.0.SummaryDifference0.2%

- Check34 days agoChange DetectedSponsor field updated from FibroGen to Kyntra Bio. FibroGen is no longer listed as sponsor.SummaryDifference0.3%

- Check41 days agoChange DetectedThe page now displays Revision: v3.3.4 added and Revision: v3.3.3 removed, indicating a minor internal version update. This change does not affect study details, eligibility criteria, or how a user interacts with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedNew Locations section added listing participating sites by state (Arizona, California, District of Columbia, Florida, Louisiana, Minnesota, Pennsylvania, Washington). The HHS Vulnerability Disclosure footer link was removed.SummaryDifference0.9%

Stay in the know with updates to Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial page.